Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zapping the brain to steady the steps of glaucoma patients?

NCT ID NCT07771699

Disease control Sponsor: The Hong Kong Polytechnic University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This trial tests whether a non-invasive brain stimulation technique, applied to the cerebellum, can improve balance and visual-cognitive function in older adults with glaucoma. Participants will receive 15 sessions of either transcranial direct current or alternating current stimulation. The study aims to see if these techniques can help the brain compensate for vision loss and reduce fall risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Non-invasive cerebellar transcranial electrical stimulation (tES), including transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation (tACS)
What this could lead to
If effective, this approach could offer a drug-free way to improve balance and reduce fall risk in older adults with glaucoma.
What could go wrong
This is a small early-stage trial, so results may not apply broadly. The stimulation may not produce lasting benefits, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 36 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Nov 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age over 55 years old; * Diagnosis of primary open-angle or normal-tension glaucoma with relative scotoma in both eyes; * Humphrey Field Analyzer visual field loss (mean deviation of ≤- 6 dB) using the 24-2 testing protocol for both eyes; * Best-corrected distance visual acuity of 6/12 (equivalent to 0.3 logMAR) or better; * Cognitive functional score of 22 or above in the Montreal Cognitive Assessment -Hong Kong version (HK-MoCA). * Only the right-handed population will be recruited (screening by the Edinburgh Handedness Inventory). Exclusion Criteria: * Have musculoskeletal disorders or neurological diseases that can affect the balance or nervous system. * Ocular diseases other than glaucoma (e.g., age-related macular degeneration, diabetic retinopathy, moderate to severe cataract) or severe hearing impairment (to ensure that participants can hear the instructions clearly during assessments and training) * Have any contraindications for tES

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glaucoma low tension glaucoma open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hong Kong Polytechnic University

    RECRUITING

    Kowloon, Hong Kong, 000000, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.